axitinib

FDA Drug Profile — AXITINIB, Axitinib, INLYTA

axitinib is listed in the FDA National Drug Code directory with 10 NDC codes, marketed under brand names including AXITINIB, Axitinib, INLYTA. Available dosage form: tablet, film coated.

Drug details

Generic Name
axitinib
Brand Names
AXITINIB, Axitinib, INLYTA
Application Number
NDA202324
Sponsor
Glenmark Pharmaceuticals Inc., USA
NDC Codes
10
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
AXITINIB

Indications and Usage

1 INDICATIONS AND USAGE INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma INLYTA in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). INLYTA in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC. 1.2 Second-Line Advanced Renal Cell Carcinoma INLYTA as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.